
Three diets that are more effective than weight-loss drugs, according to doctors
There was good news recently for anyone hoping to try the latest weight-loss injections: the NHS announced that Mounjaro will now be available through GP surgeries in England for patients with severe obesity and the 'highest clinical need'. Over the next three years, almost a quarter of a million people are expected to benefit.
GLP-1 drugs, originally designed to treat type-2 diabetes, are widely hailed as a game changer for tackling obesity. Clinical trials suggest the jabs can help users lose 15-20 per cent of their body weight. They regulate blood-sugar levels and may improve conditions linked to excess weight, including high blood pressure, fatty liver disease and sleep apnoea.
However, as the Mounjaro rollout begins, concerns are mounting among doctors and public health experts that the GLP-1 gold rush is distracting from safer, more sustainable solutions for solving the UK's ailing metabolic health. Alongside the soaring demand, reports of GLP-1 side effects are growing: from nausea and constipation to gallbladder problems and, now, hundreds of cases of pancreatitis.
'There's been a rush to embrace GLP-1 drugs as a magic bullet, but we're not talking enough about the risks,' says Dr David Unwin, award-winning GP and scientific adviser to the Public Health Collaboration (PHC), a charity that champions lifestyle-based approaches to metabolic health. 'A BMJ investigation shows there have been 82 deaths associated with these medications. Yet most patients assume the drugs are safe. People are accessing them online, without proper medical supervision. It's like the Wild West.'
While he acknowledges GLP-1s have a role to play, he and other doctors are concerned the drugs are being promoted as a fix-all, and are quietly proving that targeted diet and lifestyle programmes can achieve similar results – without side effects.
'You can stimulate your own GLP-1, naturally, through food and exercise,' says Dr Unwin, who is known for pioneering the low-carb diet for obesity and diabetes in the UK. 'A low-carb, high-protein diet is shown to boost GLP-1 levels. And it doesn't come with nausea or cost a fortune.'
Dr Campbell Murdoch is a GP with a special interest in metabolic health who launched a Metabolic Health 28-Day Plan combining a high-protein, low-carb diet with time-restricted eating, movement, easy lifestyle changes and mindset support. Originally created for NHS patients at his practice in Somerset, the results were so positive, the programme has been made freely available online.
'The GLP-1 boom has at least put metabolic health on the radar,' says Dr Murdoch. 'Now we need to give people complete solutions, including lifestyle, not just the drugs.'
Here are the three diets doctors recommend.
Low-carb diet
Key benefits: simple and sustainable
The low-carb diet is proven to get results and can curb food cravings, reverse type 2 diabetes and deliver comparable weight loss to GLP-1s, suggests latest research.
Cutting down on sugar and starchy carbs deprives the body of its primary fuel, glucose. It starts burning body fat instead, leading to weight loss. Blood-sugar levels stabilise, appetite regulates, and insulin levels fall, leading to better metabolic health and lower risk of type 2 diabetes and cardiovascular disease.
Dr Unwin has been spearheading the low-carb approach at his NHS clinic in Southport for the past 13 years, with striking results. 'On average, patients lose 10kg (22lbs) in the first year,' he says. 'We've helped 151 people achieve drug-free diabetes remission. That's 27 per cent of our diabetic population. We've saved £370,000 on diabetes medication.'
In total, 51 per cent of Dr Unwin's patients with type 2 diabetes achieve remission, another 47 per cent get better control over their condition. And over 90 per cent of patients with pre-diabetes return to normal blood-sugar levels.
Dr Unwin's approach has been adopted all over the world, through The Low-Carb Program and a free NHS-approved app.
The method is simple, says Dr Unwin. 'Eat a nutritionally dense diet that doesn't raise your blood sugar.' Officially, low carb means eating less than 130g of carbs a day (for context, one apple is 25g, a bowl of pasta 40g). However, Dr Unwin recommends focusing less on numbers and more on cutting out sugar and starchy carbs, like bread, cereals and potatoes, while increasing protein and green veg. A typical low-carb meal might be baked salmon with asparagus and cauliflower rice.
'When you eat in a way that doesn't spike blood sugar, and includes enough protein, you stay feeling full, partly through natural, GLP-1 production,' explains Dr Unwin.
Kirsten Linaker, 48, turned to the low-carb diet after weight-loss injections failed to help her. 'Dr Unwin gave me simple diet advice and a blood-glucose monitor, so I could see how foods like chocolate spiked my blood sugar,' she says. 'Now, I've lost almost 6st and have gone from size 26 to 14. I'm off my diabetic medication, and my food cravings have gone. I used to sit in bed at night, eating biscuits, now I'm just not hungry anymore. I don't even miss sweet stuff.'
If you're following a low-carb diet, be sure to include nutritious foods, rich in fibre. If you have an existing medical problem, see your GP first.
Keto diet
Key benefit: rapid results
The ketogenic, or 'keto' diet, is a more restrictive, high-fat, even lower carbohydrate approach designed to induce a fat-burning state in the body called ketosis. Followers of the diet aim for 20-50g carbs per day (drastically less than the 130g as on the low carb diet). It's proven to offer immediate weight loss and appetite suppression, along with metabolic-health benefits.
'In my experience, the keto diet gives the same benefits as GLP-1s, such as reduced appetite and elimination of food noise, without the side effects,' says Dr Eric Westman, associate professor of medicine at Duke University and director of the Duke Keto Medicine Clinic.
When carb intake is drastically restricted, the body switches into ketosis, a metabolic state in which it burns fat for fuel, by converting it to ketones. This reduces blood glucose and insulin, and lowers levels of the hunger hormone, ghrelin. People can lose several pounds in the first week, gradually slowing to a more sustainable rate.
Dr Westman's clinical research has shown that a keto diet can put type 2 diabetes into remission. Around 98 per cent of his patients with type 2 diabetes come off insulin. 'Patients typically lose one to two pounds a week,' he says. 'I can safely de-prescribe medications for diabetes, hypertension, heartburn and arthritis.'
A meta-analysis of trials, in Nutrients, found that ketogenic diets gave better weight loss and blood-sugar control than a low-carb diet.
Sharon Grey, 56, was almost 18st and living with type 2 diabetes, Nash (non-alcoholic fatty liver disease), high blood pressure and depression before she began Dr Westman's keto programme (adaptyourlifeacademy.com). After 13 months, her weight had dropped to 12st 8lb. 'I reversed my type 2 diabetes and Nash, and my blood pressure is normal again,' she says. 'My headaches, backache and knee pain improved, my mood is better and I'm taking fewer medications.'
The key to keto success is to keep carbs under 50g a day. Include plenty of protein, says Dr Westman. 'Protein is critical as it helps you feel full, and ensures you lose fat, not muscle,' he says. 'Don't overdo the dietary fat - if you eat too much of it, your body will burn that, rather than body fat.' His top five keto foods are eggs, meat or poultry, seafood, non-starchy veg (like cauliflower or broccoli) and leafy greens.
So when should you choose keto, rather than a low-carb diet? 'Keto isn't always necessary, but in severe cases, it can be beneficial,' says Dr Murdoch. 'The keto diet offers rapid results and some patients feel better on it,' adds Dr Unwin. 'However, it's more complicated than a standard, low-carb diet, and not essential for reversing type 2 diabetes.'
Transitioning to ketosis can trigger temporary fatigue and nausea, called 'keto flu'. If you're on medication, or have a medical condition, only try keto under medical supervision, advises Dr Westman.
Intermittent fasting
Key benefits: cheap and effective
If you don't like calorie counting, focusing on when you eat, rather than what you eat, could be the solution. Intermittent fasting – alternating periods of eating and fasting, such as the popular 5:2 diet – can lead to an average weight loss of five to nine per cent of body weight over three to 12 months, according to research.
'When we don't eat, the body moves into fat-release mode,' explains Dr Murdoch. 'Fasting gives the body longer to use up stored sugar and burn body fat. That's why it improves blood-sugar control, too.'
Among the most effective fasting methods is time-restricted eating (TRE), where you consume your food within a defined window each day, followed by an overnight fast. A study at Manchester Metropolitan University found that just three days on the 16:8 method (eating within an eight-hour window and fasting for 16 hours) significantly improved blood-sugar control in people with type 2 diabetes.
'TRE offers promising benefits for weight loss, glucose regulation and metabolic health – without calorie counting,' says study lead Dr Kelly Bowden Davies. 'While average weight loss is typically less than with GLP-1 drugs, prolonged use of TRE is a cheaper, safer and more accessible alternative – especially when combined with lifestyle changes.'
That's the approach taken by Dr Murdoch with his Metabolic Health 28-Day Plan. It combines time-restricted eating (11am-7pm), focusing on lower-carb (often under 70g a day), high-protein (1-2g per kilo of body weight a day) foods, daily movement (for example, squats while the kettle boils) and seven hours' sleep, presented as a tick list of 10 daily habits.
'People often lose half a stone to a stone in the first month,' says Dr Murdoch. 'Blood pressure, blood sugar, mood and energy all improve. It's as effective as GLP-1s, for a fraction of the cost, and with far better sustainability.'
Donna Brewer, 48, weighed nearly 22st when she started the plan in April. 'I'd gradually gone from a size 14 to a 24. I felt sluggish, tired, anxious, and my blood pressure was dangerously high,' she says. 'After 28 days, I'd lost almost one-and-a-half stone. Now I'm down more than 2st, my waist's shrunk from 130cm to 118cm, and I'm off medication. I feel so much happier and more energetic. It's not like a diet – more a shift in mindset.'
The health risks of GLP-1s
Using GLP-1 drugs without nutrition advice or lifestyle support can lead to malnutrition and even accelerated ageing, caution experts. 'GLP-1s reduce appetite but if you simply eat less of a regular, poor diet, you risk becoming deficient in protein and nutrients – and this drives muscle loss,' says Dr Murdoch. 'We're already seeing muscle loss and then weight regain when people stop taking the drugs.'
An Oxford University review found that most people regain the weight within 10 months of stopping GPL-1s. 'The drugs are only licensed for two years [and many patients give up earlier],' says Dr Murdoch. 'After that, if you haven't changed your habits, the weight comes back – and you've lost muscle along the way, which is hard to get back.'
In a recent clinical trial, 42 per cent of over-60s lost at least 10 per cent of their muscle power – the equivalent of ageing 7.5 years – within six months of taking the GLP-1 drug semaglutide. 'You need to pair these drugs with resistance training and proper nutrition, particularly protein,' says Dr Murdoch.
GLP-1s do have a role to play, say the doctors. 'For people addicted to ultra-processed food or who struggle to give up starchy carbs, GLP-1s can be a temporary tool, if combined with nutritional support,' says Dr Unwin. 'I recently had a 75-year-old patient who lost a stone and a half and came off insulin by combining a GLP-1 with a low-carb diet.'
However, he and other doctors are concerned the drugs are being promoted as a fix-all. 'The way weight-loss drugs are being pushed as a default solution is worrying,' says Dr David Jehring, chairman of the PHC, chief executive of Black Pear Software and creator of Elevate, a new AI personal health coach, soon to be trialled in the NHS. ' GLP-1s are now so widely available, primary care services are being told they don't need to offer dietary interventions.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Sun
24 minutes ago
- The Sun
University puts up ‘bonkers' posters warning its students not to eat conkers
A UNIVERSITY launched a 'bonkers' campaign warning its students not to eat conkers. East Anglia University has put up posters showing a conker in a red circle with a cross through it. Above the image is written, 'Do not eat conkers!' and below, 'These are not chestnuts and eating them will make you unwell'. Bosses put up the posters in the international student study centre fearing a new intake of Chinese students might think they are edible. Around 1,000 of the 17,000 students at the Norwich university hail from China. It is feared some new arrivals could confuse conkers — known as horse chestnuts — with water chestnuts, which are prized in China for their crunchy texture and mild sweetness. Horse chestnuts, however, contain a toxin called aesculin which can cause abdominal pain, nausea and vomiting. A source said: 'The uni looks out for student welfare and thought this was an area they may need guidance on.' The university said: 'As far as we're aware, no students have attempted to eat conkers and we'd like to keep it that way. 'The posters were prompted by a member of staff who previously worked with Chinese students and recalled similar confusion elsewhere. 'It's part of our broader commitment to student wellbeing.'


Daily Mirror
an hour ago
- Daily Mirror
Weight loss pill that helped patients shift 12% of body mass may soon be on NHS
A weight-loss tablet, which could be a cheaper and easier alternative to jabs and has seen patients during a trial lose up to almost 2st, could soon be available on the NHS A powerful new generation of weight-loss pill that could provide hope for millions of patients is set to be considered by regulators for NHS approval. A trial found overweight people taking the medication lost up to almost 2st – or 12% of their body weight – after 18 months. The maker, US firm Lilly, said it will seek the go-ahead by regulators for the drug orforglipron. It could be a cheaper and easier alternative to weight-loss jabs, which have to be refrigerated. The daily tablet is a GLP-1 agonist, which can cut appetite. Like jabs, the pill mimics the effects of hormones that make us feel full. Lilly also makes weight-loss jab Mounjaro. It comes after the NHS warned mouth symptom could be life-shortening disease. Kenneth Custer, of Lilly, said: 'We're working to transform obesity care with a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments. 'We are planning to submit orforglipron for regulatory review by year-end.' It will need to be approved as safe by the Medicines and Healthcare products Regulatory Agency before the National Institute for Health and Care Excellence decides if it is cost-effective for the NHS. The Mirror understands guidance is expected next year on whether it will be available on the health service. The study found 60% of people on the highest dose of orforglipron lost at least 10% of their body weight. While 40% of people shed at least 15% of their body weight. The study of 3,127 overweight adults also found benefits such as better cholesterol. Lilly said the safety profile of the tablet is similar to other GLP-1 drugs, with gastrointestinal issues the most common side effect. Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University, said: 'These early results on the effectiveness of orforglipron in promoting clinically significant weight loss are a positive step forward in the development of this class of drugs. 'Their effects on weight loss are not as profound as that seen in [jabs]. 'Nevertheless, that this medication is an oral form, rather than injectable, will likely be seen as more tolerable for many. Manufacturing costs are also anticipated to be significantly lower.' An estimated 1.5 million people in the UK use weight-loss medication, most privately. Mounjaro was due to be rolled out across the NHS in England from June 23 for those with the highest clinical need, but a probe found only eight of 42 NHS integrated care boards are providing it at present. Nearly half of boards say they will cap the number they treat due to lack of funding. NHS England says the plan is for jabs to bemore widely available. Figures suggest about 29% of adults are obese. Another new study has found GLP-1s may have other benefits such as improving Alzheimer's and liver disease.


Daily Mail
an hour ago
- Daily Mail
Long NHS waiting lists bolster profits at BUPA as it cashes in on 'growing demand' for private care
Bupa is on course to make bumper profits this year as it cashes in on 'growing demand' for private care because of lengthy NHS waiting lists. The health insurer reported a pre-tax profit of £501million for the first six months of 2025, 19 per cent higher than last year. The results, which also saw an 11 per cent jump in revenue to £8.8billion for the first half of 2025, included Bupa's operations in Europe, Latin America, India, the Middle East and Asia. The company said its performance had been bolstered by surging demand for private healthcare and income from its care homes. Inaki Ereno, group chief executive, said: 'In the first six months of the year, we have served more customers than ever before.' The half-year report also revealed that the number of people taking out Bupa's health insurance globally rose 23 per cent to 40.9m, while the occupancy rate of its care homes for older people rose 1 per cent to 94 per cent. Its UK and India division recorded turnover of £2.8billion, while profits soared 89 per cent to £126million. UK insurance accounted for 48 per cent of the division's sales, while 9 per cent came from dental practices. The company has opened 61 sites around the world, including buying New Victoria Hospital, London, its first UK hospital purchase since 2008. The growth comes as people turn to private healthcare to avoid joining the 6.2m patients languishing on NHS waiting lists. The figures, revealed last week, also showed that nearly 3m patients awaiting care had not received a first appointment with a specialist or a diagnostic test since their referral. The Patients Association described the 'invisible waiting list crisis' as 'staggering', as millions are left in limbo while their health deteriorates. Other companies which have benefited from the boom in demand from those wanting to go private include Spire, Nuffield and Circle. David Rowland, director of think-tank Centre for Health and the Public Interest, told The Guardian: 'You've now got more and more people who are having to pay out of their own pockets for things like dental care or operations that aren't available on the NHS. 'Nobody's being honest about the extent to which this is happening. No politician has stood up and advocated for it. It's a trend which has been happening increasingly over the past 30 years with Labour, Conservative and Lib Dem parties in charge.' The General Medical Council recently revealed that 19 per cent of doctors are considering a move abroad – believing the profession is 'treated better' in other countries and better-paid.